Health Professional Radio - Podcast

Dr. Stephen Brannan, Chief Medical Officer at Karuna Therapeutics discusses positive data recently published in the New England Journal of Medicine from their Phase 2 EMERGENT-1 clinical trial evaluating KarXT in adults with schizophrenia. The publication builds on previously reported Phase 2 trial results in which KarXT demonstrated clinically meaningful and statistically significant improvements in treating the positive and negative symptoms of schizophrenia. Dr. Brannan talks about how Karuna is taking a new approach to treating schizophrenia, the disease burden of schizophrenia and the unmet need among patients for a differentiated treatment option that is safe and minimizes side effects. Dr. Brannan is a neuroscience drug development expert who has held senior positions overseeing both clinical development and medical affairs with more than 15 years of industry experience. Previously, Dr. Brannan was the Therapeutic Head of Neuroscience at Takeda and Vice President for Clinical Research and Medical Affai